TLR7 and glioblastoma: Additionally, clinical studies in glioblastoma have demonstrated that the application of TLR7/8 agonists combined with GSM DHCR7/cholesterol signaling modulation significantly promotes the polarization of glioblastoma stem-like cells (GSMs) toward an anti-tumor phenotype and improves the TME.